Lytix Biopharma AS (Euronext Growth Oslo: LYTIX), a leading Norwegian
immuno-oncology company, will release its third quarter 2024 financial results
on Tuesday, 19 November 2024.

Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO
Gjest Breistein, where they will discuss the results and provide key insights.

Date: Tuesday, 19 November 2024
Time: 10:30 AM CET

Q&A Session:
We welcome your questions in advance. Please send them to
post@lytixbiopharma.com, and they will be addressed during the Q&A session
following the presentation.

Webcast Details:
The presentation and Q&A session will be conducted in English. You can view the
live event by registering here:
https://channel.royalcast.com/landingpage/hegnarmedia/20241119_7/

Missed the Live Session?
A recording of the presentation will be available shortly after the event on our
financial reports page: https://www.lytixbiopharma.com/financial-reports

For more information, please contact: 
Gjest Breistein, CFO 
+47 952 60 512
gjest.breistein@lytixbiopharma.com

About Lytix:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.